These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9427501)

  • 1. Huntington's disease gene product, huntingtin, associates with microtubules in vitro.
    Tukamoto T; Nukina N; Ide K; Kanazawa I
    Brain Res Mol Brain Res; 1997 Nov; 51(1-2):8-14. PubMed ID: 9427501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Huntington disease].
    Nukina N
    Rinsho Shinkeigaku; 1997 Dec; 37(12):1139-40. PubMed ID: 9577671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterising the Huntington's disease gene product.
    Wood J; MacMillan JC; Thomas P; Lowenstein PR; Harper PS; Jones AL
    Biochem Soc Trans; 1995 Nov; 23(4):595S. PubMed ID: 8654780
    [No Abstract]   [Full Text] [Related]  

  • 4. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease.
    Hoffner G; Kahlem P; Djian P
    J Cell Sci; 2002 Mar; 115(Pt 5):941-8. PubMed ID: 11870213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.
    Bao J; Sharp AH; Wagster MV; Becher M; Schilling G; Ross CA; Dawson VL; Dawson TM
    Proc Natl Acad Sci U S A; 1996 May; 93(10):5037-42. PubMed ID: 8643525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion.
    Smith R; Bacos K; Fedele V; Soulet D; Walz HA; Obermüller S; Lindqvist A; Björkqvist M; Klein P; Onnerfjord P; Brundin P; Mulder H; Li JY
    Hum Mol Genet; 2009 Oct; 18(20):3942-54. PubMed ID: 19628478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An intriguing new lead on Huntington's disease.
    Barinaga M
    Science; 1996 Mar; 271(5253):1233-4. PubMed ID: 8638101
    [No Abstract]   [Full Text] [Related]  

  • 8. Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
    Li SH; Li XJ
    Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
    Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
    J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH.
    Burke JR; Enghild JJ; Martin ME; Jou YS; Myers RM; Roses AD; Vance JM; Strittmatter WJ
    Nat Med; 1996 Mar; 2(3):347-50. PubMed ID: 8612237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Huntington's disease: From molecular basis to therapeutic advances.
    Krobitsch S; Kazantsev AG
    Int J Biochem Cell Biol; 2011 Jan; 43(1):20-4. PubMed ID: 21056115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.
    Muchowski PJ; Ning K; D'Souza-Schorey C; Fields S
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):727-32. PubMed ID: 11792857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of copper ion mediated Huntington's disease progression.
    Fox JH; Kama JA; Lieberman G; Chopra R; Dorsey K; Chopra V; Volitakis I; Cherny RA; Bush AI; Hersch S
    PLoS One; 2007 Mar; 2(3):e334. PubMed ID: 17396163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntingtin as an essential integrator of intracellular vesicular trafficking.
    Caviston JP; Holzbaur EL
    Trends Cell Biol; 2009 Apr; 19(4):147-55. PubMed ID: 19269181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
    Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
    J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The channel hypothesis of Huntington's disease.
    Kagan BL; Hirakura Y; Azimov R; Azimova R
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):281-4. PubMed ID: 11719262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntingtin localization in brains of normal and Huntington's disease patients.
    Sapp E; Schwarz C; Chase K; Bhide PG; Young AB; Penney J; Vonsattel JP; Aronin N; DiFiglia M
    Ann Neurol; 1997 Oct; 42(4):604-12. PubMed ID: 9382472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential distribution of the normal and mutated forms of huntingtin in the human brain.
    Gourfinkel-An I; Cancel G; Trottier Y; Devys D; Tora L; Lutz Y; Imbert G; Saudou F; Stevanin G; Agid Y; Brice A; Mandel JL; Hirsch EC
    Ann Neurol; 1997 Nov; 42(5):712-9. PubMed ID: 9392570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
    Lunkes A; Mandel JL
    Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.